Sarepta already have US$1.6bn in the bank so the closing date of the raising is irrelevant.
Sarepta also have a potential US$1.7bn in milestone payments from Roche if they get the gene therapy approved.. paying ANP a sizeable license fee to help increase the chances of those funds being received seems like good business sense don’t you!!
Also, @waynesworld, delving further into Thrombospodin 1 has got me thinking alot longer term about my investment in ANP. No wonder Graham Mitchell mentioned “assured success”.
Where others have failed will Atl1102 succeed ?, page-795
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.699M | |||
| Open | High | Low | Value | Volume |
| 0.8¢ | 0.9¢ | 0.8¢ | $20.13K | 2.276M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 26 | 6865660 | 0.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.9¢ | 1011039 | 5 |
View Market Depth
| Last trade - 16.10pm 21/07/2025 (20 minute delay) ? |
| PER (ASX) Chart |